Skip to content

TriSalus Life Sciences, Inc. TLSI Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

AngioDynamics logo
AngioDynamicsANGO
$716K-20.0%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$184K+15.7%
Delcath Systems logo
Delcath SystemsDCTH
$389K+63.4%
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
$20K+100%
LQD
Liquidia CorporationLQDA
$1.75M+38.6%
United Therapeutics logo
United TherapeuticsUTHR
$68.3M+311%

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Debt / equity2.6×
Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s stock issuance proceeds?
TriSalus Life Sciences, Inc. (TLSI) reported stock issuance proceeds of $42.63M in Q1 2026.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.